SCHEMBL6061815

SCHEMBL6061815

CC(C)N[C@@H](CS(=O)(=O)Cc1ccccc1)C(=O)NCCCCC(=O)c1nc2ccccc2s1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
HPGD P15428 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
MAPK1 P28482 1/20 0.43
HTR1A P08908 9/20 0.42
DRD2 P14416 9/20 0.42
HTR7 P34969 9/20 0.42
HTR2A P28223 8/20 0.42
SLC6A4 P31645 6/20 0.42
HTR2C P28335 3/20 0.42
HRH1 P35367 3/20 0.42
SLC6A2 P23975 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
ALOX15 P16050 1/20 0.41
TSHR P16473 1/20 0.41
CASP1 P29466 1/20 0.41
ALOX5 P09917 2/20 0.39
MAPT P10636 2/20 0.39
DRD3 P35462 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6633085 0.85 HDAC3 (0.43) HPGDMAPK1L3MBTL1ALOX15TSHR
SCHEMBL6063224 0.85 HDAC3 (0.43) HPGDMAPK1L3MBTL1ALOX15TSHR
SCHEMBL6062843 0.85 NPC1 (0.45) NPC1RAB9AHPGDSMN1; SMN2MAPK1
SCHEMBL6629355 0.83 NPC1 (0.49) NPC1RAB9AHPGDSMN1; SMN2MAPK1
SCHEMBL6629063 0.83 NPC1 (0.49) NPC1RAB9AHPGDSMN1; SMN2MAPK1
SCHEMBL6631134 0.83 DRD2 (0.44) NPC1RAB9AHPGDSMN1; SMN2MAPK1
SCHEMBL6063802 0.82 HPGD (0.44) NPC1RAB9AHPGDSMN1; SMN2MAPK1
SCHEMBL6062952 0.82 DAGLA (0.52) ALDH1A1
SCHEMBL6675832 0.79 ALOX15 (0.45) NPC1RAB9AHPGDSMN1; SMN2MAPK1
SCHEMBL6061813 0.79 ALOX15 (0.45) NPC1RAB9AHPGDSMN1; SMN2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1397340-A2 CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2004-03-17 EP claimed
WO-2002098850-A2 CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2002-12-12 WO claimed
EP-1694357-A1 USE OF CATHEPSIN S INHIBITORS FOR TREATING AN IMMUNE RESPONSE CAUSED BY ADMINISTRATION OF A SMALL MOLECULE THERAPEUTIC OR BIOLOGIC AXYS PHARMACEUTICALS, INC. (US) 2006-08-30 EP disclosed
WO-2005058348-A1 USE OF CATHEPSIN S INHIBITORS FOR TREATING AN IMMUNE RESPONSE CAUSED BY ADMINISTRATION OF A SMALL MOLECULE THERAPEUTIC OR BIOLOGIC AXYS PHARMACEUTICALS, INC. (US) 2005-06-30 WO disclosed
EP-1397340-A2 CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2004-03-17 EP disclosed
WO-2002098850-A2 CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2002-12-12 WO disclosed